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Liver safety in special populations 
 
Abstract: The FDA guidance for industry in the premarketing clinical evaluation of drug-
induced liver injury (DILI) is the most specific regulatory guidance currently available and 
has been useful in setting standards for the great majority of clinical indications involving 
subjects with a low risk of liver disorders. However, liver safety assessment faces challenges 
in populations with underlying liver disease, such as viral hepatitis or metastatic cancer. This 
is an important issue because there are currently many promising anti-viral and oncologic 
therapies in clinical development, with a trend toward oral therapies with reduced side effects. 
Without clearer guidelines, questions regarding liver safety may become a major factor in 
regulatory approval and ultimately physician uptake of the new treatments. The lack of 
consensus in defining stopping rules based on serum alanine aminotransferase (ALT) levels 
underscores the need for precompetitive data sharing to improve our understanding of DILI in 
these populations and to allow evidence-based rather than empirical definition of stopping 
rules. A workshop was convened to discuss best practices for the assessment of drug-induced 
liver injury (DILI) in clinical trials. 
 
Key points: 
 
• There is currently a lack of consensus in defining stopping rules based on serum ALT 
levels in hepatitis B and C and oncology treatment regimens 
 
• Both elevations of baseline ALT as well as ALT elevations during treatment should be 
considered when assessing the hepatotoxic potential of a candidate drug 
 
• Innovative approaches that combine clinical data from registration trials with 
biomarker, genetic and metabolomic data in appropriate patient cohorts are urgently 
required to overcome the limitations of current diagnostic paradigms 
 
 
1 Introduction: Timely detection and proper assessment of drug-induced liver injury (DILI) 
in clinical trials has for decades been one of the key safety challenges for both pharmaceutical 
industry and regulatory authorities.  
A workshop was sponsored and organized jointly by the European Innovative Medicines 
Initiative (IMI) and the Hamner Institute for Drug Safety Sciences (IDSS), with the aim of 
addressing gaps in current guidance and initiating alignment of liver safety assessment on a 
global scale.  
On November 9, 2012, regulatory experts from FDA, EMA, Health Canada, and the Japanese 
National Institute of Health Sciences discussed in Boston with representatives from industry 
and academia what could be considered best practices in clinical liver safety assessment, 
focusing on four key areas: 1) data elements and data standards, 2) methodologies to 
systematically analyze liver safety data, 3) tools and methods for causality assessment, and 4) 
liver safety assessment in special populations such as hepatitis and oncology patients.  
This section summarizes liver safety assessment challenges in populations with underlying 
liver disease, such as viral hepatitis or metastatic cancer.     
Liver chemistry elevations, typically alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), may vary over time in patients with underlying hepatitis B or C, in 
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the presence or absence of treatment. Hepatitis B flares can develop as part of the disease’s 
natural course or in response to effective treatment,  so treatment with candidate antiviral 
drugs should not be stopped unnecessarily if patients exhibit moderate liver chemistry 
elevations [1]. Numerous cancers can involve the liver and in oncology trials, patients with 
elevated pretreatment liver chemistries may require different thresholds for detecting potential 
drug-induced liver injury (DILI) and considering treatment discontinuation. Moreover, the 
risk of complications due to DILI in oncology patients needs to be balanced against the 
potential benefits of novel antineoplastic agents, underscoring the need for safety criteria that 
reliably define an unacceptable DILI risk in a patient in whom the treatment is effective. 
 
2 Viral hepatitis: Elevations of ALT > 3fold the upper limit of normal (3xULN) and ALP > 
2xULN are rare in clinical trial populations without underlying liver disease [2] and can thus 
be considered a safety signal [3]. However, approximately one-third of patients enrolling in 
chronic viral hepatitis C trials have ALT > 3xULN at baseline [4-6]. An ALT of > 3xULN 
was even shown to be a favorable prognostic factor in predicting response to peginterferon 
alpha and ribavirin (OR 1.47 vs. ALT ≤ 3xULN, p=0.003) [7]. The safety of peginterferon 
based regimens is confounded by the risk of inducing idiopathic autoimmune hepatitis in 
patients in whom this condition was previously unidentified [8]. Pre-treatment blood samples 
should be stored to facilitate the retrospective assessment of such cases. Treatment regimens 
that include ribavirin could confound interpretation of indirect hyperbilirubinemia secondary 
to hemolysis, as could regimens containing protease-inhibitors that inhibit uridine diphosphate 
glucurunosyltransferase 1A1 (UGT1A1) – especially in the presence of an underlying 
UGT1A1 gene variant in Gilbert‘s syndrome [6, 9]. Impairment of UGT1A1-mediated 
bilirubin conjugation, caused by Gilbert’s syndrome or by drugs that inhibit UGT1A1 activity, 
is associated with >50% indirect bilirubin [10, 11]. Gilbert’s syndrome is characterized by a 
concentration of total bilirubin ranging from 20 - 90 μmol/L (1.2 to 5.3 mg/dL), with a 
fraction of unconjugated bilirubin ≥ 80% [10]. These cases of hyperbilirubinemia would not 
meet Hy’s law criteria, defined as an elevation of ALT or AST ≥ 3xULN in combination with 
bilirubin > 2xULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase). In contrast, an elevation of bilirubin in the context of severe DILI reflects a 
major impairment of the liver’s excretory capacity for bilirubin and in these instances the 
fraction of direct bilirubin typically exceeds 35% [12]. 
When there are elevations in the pretreatment serum ALT, controversy exists regarding the 
use of ULN of ALT for the detection of liver injury and definition of stopping rules as 
compared to elevations relative to baseline values. The ULN has been shown to vary across 
laboratories according to methodology and the choice of reference population used to define 
the limits. An approach that examines baseline and change from baseline is believed  by some 
to provide a more quantitative and individualized measure of ALT elevation [13]. This may 
be true both for healthy populations as well as for study subjects with underlying liver disease. 
A shortcoming of the ULN is that the reference population used to establish ULN values may 
include cases of subclinical liver disease, notably non-alcoholic fatty liver disease (NAFLD). 
To date, changes from baseline have not often been used in clinical trials and therefore it is 
difficult to define stopping rules based on appropriate cutoffs. Stopping rules in clinical trials 
should be based on the extent of experience with the investigational drug or drug class, as 
well as on the background variability of liver tests in the target population. As patients can 
typically meet inclusion criteria for viral hepatitis trials with ALT values of up to 10 x ULN, 
defining stopping rules based solely on multiples of upper limit of normal can lead to 
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inconsistent stopping rules. For example, patients with a normal ALT at study entry could be 
allowed to continue in the study until their ALT reached > 10 x ULN, while patients entering 
with an ALT of 8 x ULN would have to discontinue with an elevation of only 25% over their 
baseline value. The use of a combined approach (Table 1) accounts for the level of elevation 
of ALT in the context of the patient’s baseline ALT level: 
 
Table 1: One proposed option for stopping rules during treatment for patients with chronic 
hepatitis B or C whose initial ALT before treatment is above the ULN * 
 
Baseline ALT value Elevation during treatment 
1 to less than 2 x ULN > 5 x from baseline and > 10 x ULN 
2 to less than 5 x ULN > 3 x from baseline 
Greater or equal to 5 x ULN > 2 x from baseline 
* These rules were proposed at the workshop but consensus was not reached regarding 
their endorsement. Abbreviations: ALT, alanine aminotransferase; ULN, upper limit 
of normal. 
One issue regarding use of the baseline value for normalizing enzyme elevations is that serum 
ALT will typically fall during effective treatment of hepatitis C (see Figure 1).  Since DILI 
onset is often delayed by weeks to months, it seems logical that nadir values occurring early 
in treatment might be the appropriate “baseline” reference point for subsequent elevations.  It 
was pointed out at the workshop that this would be a difficult concept to convey in a study 
protocol and would probably require real time central monitoring of the data with 
individualized stopping rules conveyed to the site. Alternatively, decisions regarding 
treatment modifications would need to be determined centrally and conveyed to the 
performance site.  It was the consensus that systems are not universally in place to allow 
either approach at this time.  
Some participants of the Working Group who convened as a follow-up to the Best Practices 
Workshop in Boston believe that in viral hepatitis trials an ALT >20x ULN should be defined 
as the stopping rule for patients whose initial value is <5x ULN. While true for hepatitis B 
virus, several investigators stated they would not be comfortable allowing a hepatitis C virus 
(HCV) patient with baseline ALT < 5xULN to progress to 20xULN on active therapy and to 
continue treatment with the study drug. This degree of ALT elevation is not normally seen in 
HCV patients unless they receive interferon treatment. If this occurred while on an 
investigational drug without interferon, the case should be viewed as suspicious of potential 
DILI. ALT elevations associated with interferon treatment are frequent, even when viral load 
is suppressed [14]. It will be interesting to see whether this is observed in the new interferon-
free direct acting antiviral regimens. The phase II and III data published for the newer 
antiviral drugs such as telaprevir, boceprevir or sobosfuvir indicate an acceptable hepatic 
safety profile, however spontaneous reports on ALT elevations typically about 8 weeks after 
initiating treatment are emerging. Finally, hepatitis virus titres determined before and during 
therapy should be taken into consideration when defining stopping rules for antiviral 
treatment. 
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3 Chronic viral hepatitis and HIV coinfection: The diagnosis of DILI in patients with HIV 
infection is challenging because of (i) treatment regimens that include potentially hepatotoxic 
drugs, (ii) a high incidence of underlying liver disease, including coinfection with hepatitis B 
or C, (iii) liver injury due to ethanol and illicit drug abuse, (iv) steatohepatitis due to insulin 
resistance, and (v) dyslipidemia caused by certain HIV medications. Moreover, the immune 
reconstitution that can result from anti-HIV treatment can also cause a flare of liver injury due 
to an immune attack on hepatocytes chronically infected with viral hepatitis. 
HIV trials have some of the highest rates of liver injury. The reported incidence of liver 
toxicity in HIV patients after initiating highly active antiretroviral therapy (HAART) ranges 
from 2 to 18% [15]. Hepatic profile analyses of ritonavir-boosted tipranavir regimens in phase 
II and III clinical trials showed grade 3/4 transaminase elevations in 11.1% of patients, with 
2.7% developing hepatic serious adverse events (SAEs) [16]. The risk was greater in patients 
with underlying liver disease. However, 84% of patients with grade 3/4 transaminase 
elevations only temporarily interrupted treatment or continued, with transaminase levels 
returning to grade ≤ 2.  The nonnucleoside reverse-transcriptase inhibitor nevirapine leads to 
ALT elevations > 5xULN in 10% of treated patients, although 6.3% remain asymptomatic 
[17]. Among 8851 subjects enrolled in 16 adult AIDS Clinical Trial Group studies, hepatitis C 
coinfection was associated with an increased risk of severe hepatotoxicity (ALT or AST > 
5xULN or total bilirubin > 2.5xULN) and baseline elevation in ALT or AST was a significant 
risk factor for severe hepatotoxicity in all regimens [18]. The protease inhibitor atazanavir is 
an inhibitor of hepatic UGT activity and hyperbilirubinemia > 2.5xULN was significantly 
associated with genetic variants of the UGT1A1 gene including the variant associated with 
Gilbert's disease [19]. 
 
4 Oncology trials: As with the newer antiviral agents, the introduction of novel anticancer 
agents into the market poses considerable challenges to the regulators with regard to liver 
safety. For example, the small molecule tyrosine kinase inhibitors (TKIs) offer great 
therapeutic potential; however, the risk of hepatotoxicity is considerable. 22 such agents have 
been approved by the US Food and Drug Administration (FDA), 19 of these also by the 
European Medicines Agency (EMA), and many more are in development or under regulatory 
review [20]. The HER2/EGFR dual tyrosine kinase inhibitor lapatinib has been associated 
with hepatotoxicity (including Hy’s law cases) in patients treated for metastatic breast cancer. 
A pharmacogenetic association with the HLA allele DQA*02:01 confers negative and 
positive predictive values of 0.97 and 0.17, respectively [21], and this could potentially allow 
pre-selection of patients likely to experience hepatotoxicity or could be useful in implicating 
lapatinib in liver injury where multiple etiologies are possible. In addition to lapatinib, the 
TKIs pazopanib, ponatinib, regorafenib and sunitinib have a boxed hepatotoxicity label 
warning. Pazopanib-induced hyperbilirubinemia is associated with the UGT1A1 TA7 
polymorphism of Gilbert’s syndrome [11]. The management of TKI-induced hepatotoxicity 
requires an individually tailored reappraisal of the risk versus the benefit of treatment and 
cannot be based solely on ALT and bilirubin cutoffs. 
There has been a major effort within GlaxoSmithKline to mine their aggregate clinical trial 
data to provide data driven cutoffs for liver safety concern [22, 23]. The aggregated dataset 
consisted of 3998 patients identified from 31 phase II and III oncology trials (the GSK 
historical oncology patient data, GSK-HOPD), and a second dataset of 18 672 patients 
without liver disease from 28 GSK phase II-IV trials (the generally healthy patient data, GSK-
GHPD). Truncated robust multivariate outlier detection (TRMOD) was used to identify 
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thresholds that define outliers for peak serum ALT and bilirubin levels. A false detection 
probability of 0.001 was used, meaning that 99.9% of the subjects from an underlying normal 
distribution are expected to be within the decision boundary, or only 0.1% of the patients are 
expected to fall outside of the decision boundary. When this statistical approach was applied 
to the 18,672 subjects without liver disease (GSK-GHPD), threshold values obtained were 
3.4x ULN for ALT and 2.1x ULN for total bilirubin [22].  It is interesting that the thresholds 
that are proposed in the FDA guidance as “Hy’s Law” criteria (ALT >3x ULN and Bili > 
2xULN), which were empirically determined, are essentially identical to the data derived 
threshold. Applying the same TRMOD approach to liver chemistry data obtained from 3998 
subjects in oncology trials [24] resulted in considerably higher thresholds: ALT >5x ULN and 
total bilirubin >2.7x ULN defined outliers in oncology patients.  These thresholds were 
therefore proposed as suitable limits to define the four quadrants of the eDISH (evaluation of 
drug-induced serious hepatotoxicity) plot, termed mDISH [24]. When the TRMOD approach 
was applied to fold baseline ALT and bilirubin data, an ALT limit of 6.9x baseline and a 
bilirubin limit of 6.5x baseline was calculated from oncology clinical trials (see figure 13 
in[25]). Parks and colleagues from GSK emphasize the weakness of employing fold ULN, 
since only peak values are considered, whereas any information regarding baseline values is 
disregarded [24]. In their view, fold elevation of baseline rather than ULN provides more 
sensitivity when identifying liver safety signals. 
The mDISH approach has been criticized [23] because the authors may have implied that the 
modified thresholds alone could be used to define a “Hy’s Law Case” whereas individual case 
causality assessment is critically important. In addition, the approach relies on all cancers 
being equivalent whereas differences in subgroups are likely. Nonetheless, all at the workshop 
agreed that guidelines for liver safety assessment in special populations should be data driven 
and that the approach taken by Parks and colleagues supported a large scale, precompetitive 
effort to aggregate the relevant historical and prospectively collected data across the industry 
and apply innovative statistical approaches to the problem.  
 
5 Conclusions: New approaches are urgently needed to identify liver safety signals in patient 
populations that exhibit baseline liver chemistry elevations. The use of standardized ALT and 
bilirubin cutoffs cannot account for the complex pathophysiology that determines phenotype 
in patients with underlying liver disease. Statistical approaches such as TRMOD can generate 
hypotheses that require validation in prospective datasets correlating new liver chemistry 
thresholds with clinical outcomes such as progression to serious liver injury. The limitations 
of ALT and bilirubin become all the more evident in patients with underlying liver disease, in 
whom deranged signaling mechanisms require innovative biomarkers for the assessment of 
prognosis. All these requirements underline the need for creating a novel liver safety research 
consortium, which combines clinical data from registration trials with biomarker, genetic and 
metabolomic data from appropriate patient cohorts. This will pave the way for defining the 
next-generation liver safety criteria required for accurate assessment of DILI in special 
populations. 
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Figure 1:  Early fall in serum ALT during effective treatment of viral hepatitis C.  Eight 
subjects with chronic viral hepatitis started treatment with an investigational treatment on day 
0, prompting a rapid fall in serum ALT that coincided with a fall in viral count (not shown).  
The arrow notes a nadir point that could be used to define the baseline values for the purpose 
of defining ALT elevations that may be drug induced. Abbreviations: ALT, alanine 
aminotransferase. 
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